deltatrials
Completed PHASE4 NCT00665834

Comparison of Rosuvastatin and Atorvastatin in Patients With Acute Coronary Syndrome

Comparison of the Effect Noted in The Apo/Apo-1 Ratio Using Rosuvastatin and Atorvastatin in Patients With acUte Coronary Syndrome CENTAURUS Study

Sponsor: AstraZeneca

Conditions Acute Coronary Syndromes Dyslipidemia
Interventions atorvastatin placebo rosuvastatin
Updated 8 times since 2017 Last updated: Mar 28, 2016 Started: Apr 30, 2006 Primary completion: Sep 30, 2007 Completion: Sep 30, 2007

Listed as NCT00665834, this PHASE4 trial focuses on Acute Coronary Syndromes and Dyslipidemia and remains completed. Sponsored by AstraZeneca, it has been updated 8 times since 2006, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Change History

8 versions recorded

  1. Jun 2025 — Present [monthly]

    Completed PHASE4

  2. Apr 2025 — Jun 2025 [monthly]

    Completed PHASE4

  3. Sep 2024 — Apr 2025 [monthly]

    Completed PHASE4

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  5. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE4

▶ Show 3 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE4

  2. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE4

  3. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE4

    First recorded

Apr 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
  • Queen's University
Data source: Queen's University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Kingston, Canada